These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The problem with the double-edged solution. Czap A Altern Med Rev; 2009 Jun; 14(2):96-8. PubMed ID: 19594219 [No Abstract] [Full Text] [Related]
43. Keeping abreast of new drug approvals and labeling changes. Rheinstein PH; Tsai VW Am Fam Physician; 1998 Sep; 58(4):995-8. PubMed ID: 9767730 [No Abstract] [Full Text] [Related]
44. FDA inspections find unsafe practices in compounding pharmacies. McCarthy M BMJ; 2013 Apr; 346():f2414. PubMed ID: 23592476 [No Abstract] [Full Text] [Related]
45. User reporting under the Safe Medical Devices Act. Arcarese JS ANNA J; 1991 Oct; 18(5):466. PubMed ID: 1953082 [No Abstract] [Full Text] [Related]
46. Overview of the ISRTP October 2014 workshop on GRAS determinations. McColl DB; Janus ER Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 2():S95-8. PubMed ID: 27392697 [TBL] [Abstract][Full Text] [Related]
47. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment. Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625 [TBL] [Abstract][Full Text] [Related]
48. Medical device regulation: an introduction for the practicing physician. Maisel WH Ann Intern Med; 2004 Feb; 140(4):296-302. PubMed ID: 14970153 [TBL] [Abstract][Full Text] [Related]
49. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
50. US Food and Drug Administration regulations governing label claims for food products, including probiotics. Saldanha LG Clin Infect Dis; 2008 Feb; 46 Suppl 2():S119-21; discussion S144-51. PubMed ID: 18181715 [TBL] [Abstract][Full Text] [Related]
51. FDA gets advice on Modernization Act compliance. Marwick C JAMA; 1998 Oct; 280(14):1214-5. PubMed ID: 9786361 [No Abstract] [Full Text] [Related]
53. FDA embraces risk-management approach. Fox JL Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383 [No Abstract] [Full Text] [Related]
54. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
55. Supplement regulations and quality. McGuffin M; Dentali S Complement Ther Med; 2006 Jun; 14(2):170; author reply 169. PubMed ID: 16765856 [No Abstract] [Full Text] [Related]
56. Correcting regulatory chaos: is there light at the tunnel's end? Marty AT J Altern Complement Med; 2003 Aug; 9(4):459. PubMed ID: 14499019 [No Abstract] [Full Text] [Related]
57. Off-label uses of drugs and medical devices: should the FDA crack down? Margolis RE Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289 [No Abstract] [Full Text] [Related]
58. A millstone in the uphill battle for credibility. Czap A Altern Med Rev; 2001 Feb; 6(1):3. PubMed ID: 11207452 [No Abstract] [Full Text] [Related]
59. FDA regulatory compliance reconsidered. Tobias C Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969 [No Abstract] [Full Text] [Related]
60. FDA on transgenic animals--a dog's breakfast? Miller HI Nat Biotechnol; 2008 Feb; 26(2):159-60. PubMed ID: 18259164 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]